## Lynne A Jones

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7293581/publications.pdf

Version: 2024-02-01

		279798	330143
38	1,554 citations	23	37
papers	citations	h-index	g-index
			1005
38	38	38	1925
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.8	32
2	Acute Rodent Tolerability, Toxicity, and Radiation Dosimetry Estimates of the S1P1-Specific Radioligand [11C]CS1P1. Molecular Imaging and Biology, 2020, 22, 285-292.	2.6	5
3	Fluselenamyl: Evaluation of radiation dosimetry in mice and pharmacokinetics in brains of non-human primate. Nuclear Medicine and Biology, 2020, 82-83, 33-40.	0.6	O
4	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	3.1	14
5	Brain microvasculature defects and Glut1 deficiency syndrome averted by early repletion of the glucose transporter-1 protein. Nature Communications, 2017, 8, 14152.	12.8	91
6	The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulation. Psychopharmacology, 2017, 234, 2019-2030.	3.1	4
7	Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorganic and Medicinal Chemistry, 2014, 22, 1700-1707.	3.0	64
8	Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate. Bioorganic and Medicinal Chemistry, 2014, 22, 2648-2654.	3.0	19
9	Positron emission tomography imaging of dopamine D2 receptors using a highly selective radiolabeled D2 receptor partial agonist. Neurolmage, 2013, 71, 168-174.	4.2	10
10	Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-2 Ligand [18F]ISO-1. PLoS ONE, 2013, 8, e74188.	2.5	41
11	Development of <sup>18</sup> F-Labeled PET Probes for Imaging Cell Proliferation. Current Topics in Medicinal Chemistry, 2013, 13, 892-908.	2.1	10
12	Radiolabeled isatin binding to caspase-3 activation induced by anti-Fas antibody. Nuclear Medicine and Biology, 2012, 39, 137-144.	0.6	22
13	Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. Nuclear Medicine and Biology, 2011, 38, 725-739.	0.6	14
14	Characterization and Evaluation of Two Novel Fluorescent Sigma-2 Receptor Ligands as Proliferation Probes. Molecular Imaging, 2011, 10, 7290.2011.00009.	1.4	37
15	Endogenous dopamine (DA) competes with the binding of a radiolabeled D <sub>3</sub> receptor partial agonist in vivo: A positron emission tomography study. Synapse, 2011, 65, 724-732.	1.2	39
16	Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorganic and Medicinal Chemistry, 2011, 19, 1666-1673.	3.0	55
17	Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. Molecular Imaging, 2011, 10, 420-33.	1.4	22
18	Evaluation of 5-ethynyl-2′-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system. Brain Research, 2010, 1319, 21-32.	2.2	172

#	Article	IF	CITATIONS
19	Radiosynthesis and biological evaluation of a promising $led{l}f2$ -receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. Applied Radiation and Isotopes, 2010, 68, 2268-2273.	1.5	28
20	[ <sup>3</sup> H]4â€(dimethylamino)â€ <i>N</i> à€(4â€(4â€(2â€methoxyphenyl)piperazinâ€1â€yl) butyl)benzar selective radioligand for dopamine D <sub>3</sub> receptors. II. Quantitative analysis of dopamine D <sub>3</sub> and D <sub>2</sub> receptor density ratio in the caudateâ€putamen. Synapse, 2010, 64, 449-459.	nide: A 1.2	34
21	Click Synthesis and Biologic Evaluation of ( $\langle i\rangle R\langle i\rangle$ )- and ( $\langle i\rangle S\langle i\rangle$ )-2-Amino-3-[1-(2-[ $\langle sup\rangle 18\langle sup\rangle F$ ]Fluoroethyl)-1 $\langle i\rangle H\langle i\rangle$ -[1,2,3]Triazol-4-yl]Propanoic Acid for Brain Tumor Imaging with Positron Emission Tomography. Molecular Imaging, 2010, 9, 7290.2010.00025.	1.4	27
22	Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nuclear Medicine and Biology, 2010, 37, 509-516.	0.6	48
23	[ <sup>3</sup> H]4â€{Dimethylamino)â€ <i>N</i> à€[4â€(4â€(2â€methoxyphenyl)piperazin―1â€yl)butyl]benzai selective radioligand for dopamine D <sub>3</sub> receptors. I. In vitro characterization. Synapse, 2009, 63, 717-728.	mide, a 1.2	27
24	New N-substituted 9-azabicyclo [3.3.1] nonan-3 $\hat{l}$ ±-yl phenylcarbamate analogs as $\hat{l}$ f2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. Bioorganic and Medicinal Chemistry, 2009, 17, 1222-1231.	3.0	40
25	Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography. Nuclear Medicine and Biology, 2009, 36, 651-658.	0.6	40
26	Synthesis and in Vitro and in Vivo Evaluation of $\sup 18 \le \sup 5$ . Synthesis and in Vitro and in Vivo Evaluation of $\sup 5$ . Synthesis and in Vitro and in Vivo Evaluation of $\sup 5$ . Chemistry, 2009, 52, 1358-1369.	6.4	48
27	Fluorine-18-Labeled Benzamide Analogues for Imaging the $\ddot{l}f2$ Receptor Status of Solid Tumors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2007, 50, 3194-3204.	6.4	102
28	Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Molecular Cancer, 2007, 6, 48.	19.2	118
29	Synthesis and evaluation of a bromine-76-labeled PPARγ antagonist 2-bromo-5-nitro-N-phenylbenzamide. Nuclear Medicine and Biology, 2006, 33, 847-854.	0.6	17
30	Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5041-5046.	2.2	116
31	[3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: A novel sigma-2 receptor probe. European Journal of Pharmacology, 2005, 525, 8-17.	3.5	60
32	Carbon-11 labeled Ïf2 receptor ligands for imaging breast cancer. Nuclear Medicine and Biology, 2005, 32, 423-430.	0.6	67
33	MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Nuclear Medicine and Biology, 2002, 29, 783-790.	0.6	54
34	Effect of administration route on FES uptake into MCF-7 tumors. Nuclear Medicine and Biology, 2001, 28, 397-399.	0.6	7
35	Comparison of animal models for the evaluation of radiolabeled androgens. Nuclear Medicine and Biology, 2001, 28, 613-626.	0.6	19
36	Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline). Investigational New Drugs, 1997, 15, 187-194.	2.6	12

#	Article	IF	CITATIONS
37	Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents. International Journal of Pharmacognosy, 1995, 33, 102-122.	0.2	32
38	Antitumour activity of N-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl]methanesulfonamide (WIN33377) and analogues. Expert Opinion on Investigational Drugs, 1994, 3, 1281-1292.	4.1	7